Thank you and welcome, everyone, to the webcast for Ascelia Pharma's Q2 report for 2027. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma and recent key events, and then head into our portfolio update with an emphasis on the recent Complete Response Letter for Orviglance before moving to financials and priorities ahead. After the presentation, we will open the floor for questions.
At Ascelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We are based in Malmö, Sweden, and we are listed on Nasdaq Stockholm. We have two drugs in our pipeline. Orviglance is a diagnostic drug, and we have submitted a new drug application to the FDA to obtain approval in the US. We received a Complete Response Letter in early July and will meet with the FDA on September 9th to find the path to approval. Oncoral is a patented tablet formulation of irinotecan, with encouraging results in phase 1 and the potential to treat a range of solid tumors. In April, we raised 20 million Swedish kronor in a directed share issue, and in May, we held our annual general meeting as usual. In June, Orviglance data was presented at the ESGAR conference, the major European conference for Gastrointestinal and Abdominal Radiology. At the end of the quarter, we filed a patent application regarding packaging and manufacturing, and thus further strengthened the IP position of Orviglance.
After the end of the second quarter, we received a Complete Response Letter from the FDA regarding our new drug application submission for Orviglance. This was unexpected, and we will talk more about it later in this call. We also announced that our Chief Financial Officer, Anton Hansson, will be leaving Ascelia Pharma and that we have implemented cost reductions. We have implemented cost reduction actions to improve our financial flexibility. I'd like to thank Anton for his contributions and wish him the best of luck going forward. We will start the portfolio section of our presentation with Orviglance. Despite the setback with the Complete Response Letter, we continue to be excited by Orviglance and here is why. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This is an $800 million global addressable market opportunity, with Orviglance as a first-in-class product to target this, and the product has orphan drug designation from the FDA. We have not. We have commercial-scale manufacturing in place, and we have strong data from nine clinical studies, including compelling phase three data. As mentioned, the Orviglance new drug application has been submitted to the FDA and undergone the review process. Unfortunately, the FDA sent a Complete Response Letter with some specific issues, but many areas of the new drug application were reviewed that did not result in issues being raised. Our focus is on agreeing with the FDA on what is required to obtain approval for Orviglance. Orviglance is an attractive asset, and we will work with a partner who will drive the commercialization once the product is approved. Based on the NDA submission and the data, we remain confident in the clinical profile of the product. The unmet medical need that Orviglance addresses. The progress of the review process, including the audits conducted. We were expecting an approval of Orviglance in July. In the Complete Response Letter, the FDA raised some issues that we will discuss with them at a Type A meeting in September, so we can find an efficient path forward for Orviglance. We continue to be confident that the Orviglance new drug application is supported by substantial evidence of efficacy and safety for its intended patient population, which we think should support approval, and we are committed to bringing Orviglance to patients. We will now go into more details on the regulatory process, and I would like to hand over to Andreas.